Eli Lilly stacking scientists in San Diego as part of R&D growth spurt
- By next year, Lilly plans to add 175,000 square feet of space to the Lilly Biotechnology Center.
- Eli Lilly is based in Indianapolis, but has had a presence in San Diego for 11 years ever since it acquired Applied Molecular Evolution.
- Lilly plans to take advantage of San Diego's ideal location in terms of the available pool of talented biomedical researchers and academic institutions, and will be adding 130 scientists to the San Diego location.
Lilly had marginally better sales for quarter over quarter for Q2 2015 and has high hopes for gaining several key approvals in the near future. Currently, the company is focused on bringing its promising late-stage pipeline to fruition, including the psoriasis drug, ixekizumab—an IL-17 antibody. In addition, there continues to be excitment around the rheumatoid arthritis drug baricitinib, as well as necitumumab, which is in late-stage development for advanced squamous non-small cell lung cancer (NSCLC).
Lilly is looking to add more research professionals with various areas of expertise, including disovery chemistry, research technology and biotech. Ultimately, the goal for Lilly is to make a comeback as a company with a strong growth trajectory, thereby overcoming the impact of generic competition.